{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-004526","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.279001+00:00","generated_at":"2026-06-01T01:17:47.684342+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aethlon Medical reports FY2024 net loss of $12.2M; cash at $9.1M; oncology trial approved","bullets":["Net loss of $12.2M for FY ended March 31, 2024, compared to $12.0M in FY2023.","Cash balance of $5.4M at March 31, 2024, increased to $9.1M as of June 25, 2024.","Received HREC ethics approval for Hemopurifier safety/feasibility oncology trial in Australia, valid through 2027.","FDA approved internal manufacturing facility in April 2024.","COVID-19 trial in India remains open with one patient treated; monitoring H5N1 avian flu situation."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-004526","json":"https://secwatch.observer/filing/0001683168-24-004526.json","markdown":"https://secwatch.observer/filing/0001683168-24-004526.md","text":"https://secwatch.observer/filing/0001683168-24-004526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316824004526/0001683168-24-004526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316824004526/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:17:47.684342+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}